Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 11/20 | 0.57 |
| ▸ | EPHB4 | P54760 | 11/20 | 0.57 |
| ▸ | FLT1 | P17948 | 10/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.57 |
| ▸ | EGFR | P00533 | 6/20 | 0.55 |
| ▸ | GAK | O14976 | 1/20 | 0.55 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.55 |
| ▸ | STK10 | O94804 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | YES1 | P07947 | 1/20 | 0.55 |
| ▸ | LYN | P07948 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | HCK | P08631 | 1/20 | 0.55 |
| ▸ | BCR | P11274 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17880567 | 0.90 | KDR (0.58) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL17378104 | 0.89 | TRPA1 (0.53) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL371845 | 0.88 | AXL (0.61) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL10245018 | 0.86 | KDR (0.47) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL19711812 | 0.84 | TRPA1 (0.46) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL372077 | 0.83 | KDR (0.49) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL2744934 | 0.83 | EGFR (0.57) | KDREPHA2EPHB4FLT1ERBB2 | |
| SCHEMBL5824789 | 0.82 | TRPA1 (0.76) | KDREGFRLCKRETTRPA1 | |
| SCHEMBL14771291 | 0.80 | TRPA1 (0.64) | KDRFLT1EGFRGAKRET | |
| SCHEMBL14771309 | 0.80 | TRPA1 (0.64) | KDRFLT1EGFRGAKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8178532-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8067436-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | KDR 4/4885EPHA2 610/4885EPHB4 207/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | KDR 4/4885EPHA2 610/4885EPHB4 207/4885 |
| US-20120022065-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | KDR 5/4885EPHA2 834/4885EPHB4 336/4885 |
| US-20140155378-A9 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | KDR 5/4885EPHA2 834/4885EPHB4 336/4885 |
| US-20140155396-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | KDR 5/4885EPHA2 834/4885EPHB4 336/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | KDR 4/4885EPHA2 610/4885EPHB4 207/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | KDR 4/4885EPHA2 610/4885EPHB4 207/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | KDR 4/4885EPHA2 610/4885EPHB4 207/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | KDR 5/4885EPHA2 746/4885EPHB4 329/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | KDR 5/4885EPHA2 834/4885EPHB4 336/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | KDR 5/4885EPHA2 834/4885EPHB4 336/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | KDR 5/4885EPHA2 834/4885EPHB4 336/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | KDR 4/4885EPHA2 610/4885EPHB4 207/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | KDR 5/4885EPHA2 746/4885EPHB4 329/4885 |
| US-20130252940-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | KDR 5/4885EPHA2 834/4885EPHB4 336/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | KDR 5/4885EPHA2 834/4885EPHB4 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.